CORRECTED-UPDATE 2-Novo hikes forecasts on hopes for new blockbuster drug
(In third paragraph, corrects 2012 net profit to "up 25 percent to 21.4 billion Danish crowns", from "up 23 percent to 5.80 billion".)
* Q4 EBIT 7.57 bln DKK, vs 7.11 bln forecast
* Raises 2013 full-year guidance
* Says to launch new share buy-back of up to 14 bln DKK
* Shares rise 0.1 percent
COPENHAGEN, Jan 31 (Reuters) - The world's biggest insulin producer Novo Nordisk raised sales and profit forecasts for 2013 on hopes its new Tresiba drug will soon win approval in the United States and add further momentum to surging profits.
The Danish firm said on Thursday it expected 2013 sales growth in local currencies of between 8 percent and 11 percent and operating profit growth of around 10 percent. Its previous guidance had been for single-digit growth in each.
It also posted 2012 net profit up 25 percent to 21.4 billion Danish crowns ($3.9 billion), the highest in the company's history.
On Tresiba, chief executive Lars Rebien Sorensen said: "I have the anticipation that this will be a multi-billion dollar blockbuster drug."
Tresiba has already been approved in Europe and Japan but there had been concern about its future in the U.S. market after regulators there said last November that its key component degludec had a higher heart safety risk than other diabetes treatments.
However an advisory panel to the U.S. Food and Drug Administration subsequently voted to recommend approval of degludec, despite the signals of possible cardiovascular risk.
"For Tresiba, we have a good portion of sales included in our guidance, but the largest part of that is from the United States," Sorensen said.
"Whether we will be able to launch in the second quarter or it is deferred to the third quarter has some implications on the top line of the company," Sorensen said.
Any setback for Tresiba, would be good news for rival Sanofi , whose Lantus product currently dominates the long-acting insulin market and had 2011 sales of around $5 billion.
It could also be positive for Eli Lilly, which is developing a rival drug that is a few years behind.
Novo Nordisk said fourth-quarter earnings before interest and tax (EBIT) rose a quarter to 7.57 billion Danish crowns ($1.38 billion), compared with a forecast for 7.11 billion in a Reuters poll.
"The fourth quarter was another blow-out result and growth was extremely good," Alm Brand analyst Michael Jorgensen said.
The result was helped by a 29 percent rise in sales of diabetes treatment Victoza to 2.71 billion crowns, against a forecast for 2.85 billion, and a 20 percent increase in the sale of modern, or synthetic, insulins, in line with expectations.
Novo Nordisk shares were down 0.1 percent at 0910 GMT, tracking a 0.2 percent fall in Copenhagen's benchmark index .
"It is a strong result from Novo Nordisk," said Sydbank analyst Soren Hansen. "Expectation to the report were sky high and I think they met those expectations."
Sales grew 16 percent to 20.96 billion crowns, slightly above analysts' average 20.86 billion crowns estimate.
The group said it would initiate a new share buy-back programme of up to 14 billion crowns and raised the dividend 29 percent to 18 crowns.
Earlier this week, rival Eli Lilly and Co reported a fall in fourth-quarter profit as competition from generic drugs, particularly for its once top-selling schizophrenia drug Zyprexa, drove revenue lower. ($1 = 5.4980 Danish crowns) ($1 = 5.4980 Danish crowns) (Additional reporting by Shida Chayesteh and Johan Ahlander; Editing by Sophie Walker)